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a b s t r a c t
The (þ)-isomer of indeloxazine AS1069562 exerts multiple pharmacological actions including the
inhibition of serotonin (5-HT) and norepinephrine reuptake and analgesia in experimental animal pain
models. Here, we evaluated the antinociceptive effects of AS1069562 and the antidepressants duloxetine
and amitriptyline in mouse models of prostaglandin-induced spinal hypersensitivity. Prostaglandin E2
(PGE2) and F2α (PGF2α) were intrathecally administered to induce spinal hypersensitivity, causing tactile
allodynia in mice. Allodynia induced by PGF2α but not by PGE2 was suppressed by desensitization of
C-ﬁbers with systemic pretreatment with resiniferatoxin. C-ﬁber hyperexcitability might therefore play a
role in allodynia induced by PGF2α but not PGE2. In the PGE2-induced allodynia model, AS1069562 and
duloxetine signiﬁcantly suppressed allodynia, whereas amitriptyline did not. In the PGF2α-induced
allodynia model, AS1069562 and amitriptyline signiﬁcantly ameliorated allodynia, whereas duloxetine
did not. To demonstrate the broad effects of AS1069562 compared to duloxetine, additional studies were
conducted to elucidate other target mechanisms of AS1069562 beyond 5-HT and norepinephrine
reuptake inhibition. AS1069562 exhibited afﬁnity for both 5-HT1A and 5-HT3 receptors, and the analgesic
effect of AS1069562 on PGF2α-induced allodynia was signiﬁcantly blocked by the 5-HT1A receptor
antagonist (S)–WAY100135 and the 5-HT3 receptor agonist SR57227. Taken together, these results
indicate that AS1069562 inhibits both C-ﬁber- and non-C-ﬁber-dependent prostaglandin-induced
allodynia, while duloxetine inhibits only non-C-ﬁber-triggered allodynia, and amitriptyline inhibits only
C-ﬁber-triggered allodynia. These broad antinociceptive effects of AS1069562 may be due not only to 5-HT
and norepinephrine reuptake inhibition but also to its effects on 5-HT receptors such as 5-HT1A and 5-HT3
receptors.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Antidepressants such as the serotonin (5-HT) and norepinephr-
ine reuptake inhibitor duloxetine and the tricyclic antidepressant
amitriptyline are currently used to treat chronic pain, such as
neuropathic pain. The analgesic effects of these antidepressants
are based on the enhancement of the serotonergic and noradre-
nergic descending inhibition system (Thor et al., 2007), which
presynaptically inhibit glutamate release at the spinal cord
(Yoshimura and Furue, 2006).
Indeloxazine is a cerebral metabolic enhancer with multiple
pharmacological effects, such as 5-HT and norepinephrine reup-
take inhibition (Yamamoto, 1990). AS1069562 is the optical
(þ)-isomer of indeloxazine and also exerts inhibitory effects
against 5-HT and norepinephrine reuptake (Shimizu-Sasamata
et al., 1993). We recently found that AS1069562 signiﬁcantly
improved both mechanical allodynia and thermal hyperalgesia in
a rat model of chronic constriction injury (CCI)-induced neuro-
pathic pain. In contrast, duloxetine only induced a signiﬁcant
amelioration of mechanical allodynia, while amitriptyline signiﬁ-
cantly ameliorated thermal hyperalgesia. Further, AS1069562
increased the ratio of both 5-HT and norepinephrine to their
metabolites contents in the rat spinal cord, while duloxetine
slightly increased only the ratio of 5-HT to its metabolite contents
(Murai et al., 2014). Although these results imply that AS1069562
may have distinct spinal analgesic mechanisms compared with
duloxetine and amitriptyline, no such mechanism has been
elucidated.
Mouse models of intrathecal (i.t.) prostaglandin-induced allodynia
are useful in investigating spinal antinociceptive mechanisms of
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analgesics, as their evaluation in a pure allodynic state facilitates the
identiﬁcation of active sites in the pain pathway. Intrathecal injection
of prostaglandin E2 (PGE2) or prostaglandin F2α (PGF2α) induce tactile
allodynia, a clinically important manifestation of neuropathic pain,
by facilitating glutamate release from presynaptic terminals at the
spinal cord dorsal horn via prostaglandin E receptor 1 (EP1) and
prostaglandin F receptor (FP), respectively (Minami et al., 1992,
1994a, 1994b; Muratani et al., 2003; Tsukamoto et al., 2010).
In this study, ﬁrst, we conﬁrmed the dose-dependent induction
of tactile allodynia including their time course via i.t. administra-
tion of PGE2 and PGF2α in mice. In addition, to investigate the
dependence of C-ﬁber hyperexcitability in these spinal hypersen-
sitivity models, we examined the effects of resiniferatoxin (RTX),
an ultrapotent analog of capsaicin. After these validative experi-
ments, we assessed the antinociceptive effects of AS1069562,
duloxetine, and amitriptyline in these models to determine the
different spinal antinociceptive mechanisms of these drugs.
Further, to determine whether or not AS1069562 exerts its activity
via different mechanisms from its 5-HT and norepinephrine
reuptake inhibition, we investigated the possible involvement of
cross activity for 5-HT receptor subtypes in the antinociceptive
effect using spinal pharmacological tools, a 5-HT1A receptor
antagonist and a 5-HT3 receptor agonist. The results of this study
provided novel mechanistic aspects of AS1069562 different from a
selective 5-HT and norepinephrine reuptake inhibitor, duloxetine.
2. Materials and methods
2.1. Drugs
(R)-2-[(1 H-inden-7-yloxy)methyl]morpholine monobenzene-
sulfonate (AS1069562) and duloxetine were synthesized at Astel-
las Pharma Inc. (Ibaraki, Japan). Hydrochloride salts of AS1069562
and duloxetine were used as AS1069562 and duloxetine, respec-
tively. Amitriptyline, RTX, PGE2, and PGF2α were purchased from
Sigma-Aldrich (St. Louis, MO, USA). The 5-HT1A receptor antagonist
(S)–WAY100135 and 5-HT3 receptor agonist SR57227 were pur-
chased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
For in vivo studies, AS1069562, duloxetine, and amitriptyline were
suspended in distilled water and administered at an oral (p.o.)
dose of 10 ml/kg. AS1069562 and duloxetine were administered at
3, 10, and 30 mg/kg, while amitriptyline was administered at 10,
30, and 100 mg/kg as previously reported (Katoh et al., 1995;
Shimizu-Sasamata et al., 1993). RTX was suspended in solution of
10% EtOH, 10% Tween 80, and 80% saline and was administered at a
subcutaneous (s.c.) dose of 0.001 mg/10 ml/kg. (S)–WAY100135
and SR57227 were suspended in saline and administered at an i.t.
dose of 2 nmol/5 μl/animal. PGE2 and PGF2α were dissolved in
ethanol, and an aliquot of the desired solution was evaporated
under nitrogen gas to remove the ethanol. PGE2 and PGF2α were
then dissolved in saline and administered at an i.t. volume of 5 μl/
animal. PGE2 was administered at 1, 10, and 100 ng/animal, and
PGF2α at 100, 300, and 1000 ng/animal to investigate dose depen-
dency. PGE2 was administered at 10 ng/animal and PGF2α at
300 ng/animal for drug evaluation. Drug concentrations were
calculated in terms of free base.
2.2. Animals
Male imprinting control region (ICR) mice (18–22 g; Japan SLC,
Hamamatsu, Japan) were used for in vivo experiments. Animals
were group-housed under a 12-h light-dark cycle (light on: 7:30–
19:30) at room temperature (2371 1C) with free access to food
and water. All animal experimental procedures were approved by
the Committee for Animal Experiments of Astellas Pharma Inc.,
and all efforts were made to minimize the number of animals used
as well as their suffering.
2.3. Binding assay
Binding assays were conducted using rat cerebral cortex (5.0 mg
of protein) for the 5-HT1A receptor, rat whole brain (5.0 mg of
protein) for the 5-HT1B receptor, human recombinant 5-HT2B recep-
tor (7.0 mg of protein; Perkin Elmer, Boston, MA, USA), and human
recombinant 5-HT3 receptor (2.5 mg of protein; Perkin Elmer). For the
5-HT1A receptor binding assay, [Propyl-2,3-ring-1,2,3-3H]-8-hydroxy-
DPAT (0.47 nM; Perkin Elmer) and competitor (5-HT hydrochloride;
Sigma-Aldrich) were incubated at 37 1C for 30 min in 50 mM Tris-
HCl buffer (pH 7.4). For the 5-HT1B receptor binding assay, [125I]iodo-
(7)-cyanopindolol (0.01 nM; Perkin Elmer) and competitor (5-HT
hydrochloride; Sigma-Aldrich) were incubated at 25 1C for 60 min in
50 mM Tris-HCl buffer (pH 7.4). For the 5-HT2B receptor binding
assay, 2-(þ)-[125I]iodo-lysergic acid diethylamide (0.27 nM; Perkin
Elmer) and competitor (5-HT hydrochloride; Sigma-Aldrich) were
incubated at 37 1C for 30 min in 50 mM Tris-HCl buffer (pH 7.4)
containing 4 mM CaCl2. For the 5-HT3 receptor binding assay,
[N-methyl-3H]–GR65630 (0.48 nM; Perkin Elmer) and competitor
(MDL72222, 5-HT3 receptor antagonist; Sigma-Aldrich) were incu-
bated at 25 1C for 60 min in 50 mM Tris-HCl buffer (pH 7.4) contain-
ing 5 mMMgCl2 and 1 mM EDTA. To determine non-speciﬁc binding,
100 mM 5-HT hydrochloride for 5-HT1A, 5-HT1B, or 5-HT2B receptor,
or 100 mM MDL72222 for 5-HT3 receptor was used. Incubated
mixtures were ﬁltered using a cell harvester. The ﬁlter paper was
rinsed three times with 50 mM Tris-HCl buffer (pH 7.4), and the
radioactivity of paper was determined via scintillation counting.
Speciﬁc binding was deﬁned as a portion of total binding, which
was replaced by 100 mM 5-HT hydrochloride for the 5-HT1A, 5-HT1B,
or 5-HT2B receptor, or MDL72222 for 5-HT3 receptor. Dissociation
constant (Kd) and binding site density (Bmax) were calculated via
Scatchard analysis. IC50 values were calculated from the non-linear
regression analysis. Values of the apparent equilibrium dissociation
constant of inhibitors (Ki) were calculated using the method of Cheng
and Prusoff (1973).
2.4. Intrathecal prostaglandin-induced allodynia model in mice
The prostaglandin-induced spinal hypersensitivity model was
induced as previously described (Tsukamoto et al., 2010). Mice
were randomly divided into various groups, with eight animals per
group. A 30-gauge stainless steel needle attached to a microsyr-
inge was inserted between the L5 and L6 vertebrae of conscious
mice, and a prostaglandin (PGE2 or PGF2α in saline at a volume of
5 μl) was slowly administered via i.t. injection into the subarach-
noid space (Hylden and Wilcox, 1980). Saline was used as a vehicle
control of PGE2 and PGF2α. Tactile hypersensitivity was assessed 5,
10, 15, and 30 min after i.t. injection of prostaglandin by lightly
stroking the ﬂank of the mice with a paintbrush. The allodynia
response was ranked as 0 (no response), 1 (avoidance), or 2
(vigorous squeaking or strong avoidance), with scores expressed
as a percentage of the maximum possible cumulative score for all
time points. To conﬁrm the dose-dependent induction of tactile
allodynia, the following doses were administered: PGE2 at 1, 10,
and 100 ng/animal and PGF2α at 100, 300, and 1000 ng/animal.
Doses of prostaglandins (i.t.) that produced a submaximal allodynic
response (PGE2: 10 ng/animal; PGF2α: 300 ng/animal) were selected.
To investigate the involvement of C-ﬁber in prostaglandin-induced
hypersensitivity, we examined desensitization of C-ﬁbers with RTX.
RTX (0.001 mg/kg s.c.) was administered for 24 h prior to prosta-
glandin injection, thereby desensitizing C-ﬁbers. A solution of 10%
EtOH, 10% Tween 80, and 80% saline was used as a vehicle control for
RTX. To assess their analgesic effects on prostaglandin-induced spinal
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hypersensitivity, AS1069562 (3, 10, and 30 mg/kg) was orally admi-
nistered at 30 min prior, duloxetine (3, 10 and 30 mg/kg) at 240 min
prior, and amitriptyline (10, 30 and 100 mg/kg) at 60 min prior to
prostaglandin injection. Pretreatment with AS1069562, duloxetine,
or amitriptyline at these time points enabled almost the maximum
concentration level of each to be obtained (Murai et al., 2014;
Yamaguchi et al., 1998). Distilled water was used as a vehicle control
for AS1069562, duloxetine, or amitriptyline. In the mechanistic study
of AS1069562, the 5-HT1A receptor antagonist (S)–WAY100135
(2 nmol) and 5-HT3 receptor agonist SR57227 (2 nmol) were admi-
nistered (i.t.) 30 min prior to the PGF2α injection to determine
whether or not AS1069562 activates the 5-HT1A receptor and inhibits
the 5-HT3 receptor at the spinal cord. Saline was used as a vehicle
control of (S)–WAY100135 and SR57227. Eight rats were used in each
experimental group. The number of animals was determined in a
preliminary study to reproduce the drug efﬁcacy and minimize the
number of animals necessary for the study.
2.5. Statistical analysis
Data are expressed as the mean7the standard error of the
mean (S.E.M.). Normal group is i.t. vehicle-treated and s.c. or p.o.
vehicle-treated group. Control group is i.t. prostaglandin-treated
and s.c. or p.o. vehicle-treated group. Signiﬁcant differences
between the two groups (normal group vs. control group
(Figs. 2–5), control group vs. RTX-treated group (Fig. 2), control
group vs. AS1069562-treated group (Fig. 5), AS1069562-treated
group vs. AS1069562 and 5-HT1A antagonist or 5-HT3 agonist-
treated group (Fig. 5)) were assessed using Student's t test, while
those among more than two groups (i.t. vehicle-treated group vs.
prostaglandin-treated groups (Fig. 1B), control group vs. drug-
treated groups (Figs. 3 and 4)) were assessed using one-way
analysis of variance followed by Dunnett’s multiple comparison
post-test. Po0.05 was considered signiﬁcant.
3. Results
3.1. Binding afﬁnities for 5-HT receptors
To determine whether or not AS1069562 has mechanisms
other than those for 5-HT and norepinephrine reuptake inhibition
contributing to its different ranges of analgesic effects from
duloxetine, we investigated the binding afﬁnities of AS1069562
and duloxetine for 5-HT receptors using rat or human 5-HT1A,
5-HT1B, 5-HT2B, and 5-HT3 receptors. The Ki values of AS1069562
and duloxetine for 5-HT receptors are listed in Table 1.
In synaptosomal preparations of rat brain, AS1069562 inhibited
5-HT uptake with an IC50 value of 0.83 μM and norepinephrine
uptake with an IC50 value of 6.8 μM (Shimizu-Sasamata et al.,
1993). Further, duloxetine inhibited 5-HT uptake with an IC50
value of 0.0026 and norepinephrine uptake with an IC50 value of
0.0070 μM (Wong et al., 1993). Compared to the inhibition of 5-HT
and norepinephrine uptake, the respective approximate afﬁnities
of AS1069562 for each of the 5-HT receptors were as follows: 1.7-
and 0.21-fold lower (5-HT1A receptor), 3.0- and 0.37-fold lower
(5-HT1B receptor), 1.8 and 0.22-fold lower (5-HT2B receptor), and
3.1- and 0.38-fold lower (5-HT3 receptor). Compared to the
inhibition of 5-HT and norepinephrine uptake, the respective
approximate afﬁnities of duloxetine for binding 5-HT receptors
were as follows: 1692- and 629-fold lower (5-HT1A receptor),
1308- and 486-fold lower (5-HT1B receptor), 154- and 57-fold
lower (5-HT2B receptor), and 5769- and 2143-fold lower (5-HT3
receptor). These results indicate that the potencies of AS1069562
for binding 5-HT receptors and inhibiting 5-HT and norepinephr-
ine uptakes are similar (0.21- to 3.1-fold difference), while those of
duloxetine are different (57- to 5769-fold difference).
3.2. Prostaglandin-induced allodynia in mice
To determine the appropriate time course and dose of pros-
taglandin for drug evaluation, we evaluated the dose dependent
Fig. 1. Tactile allodynia in mice following intrathecal injection of PGE2 (a) and PGF2α (b). (A) Time course of allodynia induction from 5 to 30 min after i.t. injection of PGE2
(1, 10, and 100 ng/animal) (a) or PGF2α (100, 300, and 1000 ng/animal) (b). (B) Dose-dependency of PGE2 (a) or PGF2α (b) in cumulative allodynia scores within 30 min of i.t.
stimulation. Intrathecal injection of PGE2 and PGF2α induced allodynia in a dose-dependent manner from 5 to 30 min after i.t. injection. Data (the mean7S.E.M. for 8 mice)
are presented as percentage of the maximum cumulative score. Vehicle (black column) represents i.t. injection of saline. nnPo0.01, nnnPo0.001 by Dunnett's test compared
with vehicle-treated group.
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efﬁcacies in prostaglandin-induced allodynia models over a 30 min
period. Tactile allodynia, which is induced by spinal hypersensitivity,
was obvious within 5 min of i.t. injection of PGE2 (10 and 100 ng) or
PGF2α (100, 300 and 1000 ng), and sustained for 30 min (Fig. 1A). Both
PGE2 and PGF2α induced allodynia in a dose-dependent manner
(Fig. 1B). Near-maximum allodynic effects were observed with 10 ng
of PGE2 and 300 ng of PGF2α, ﬁndings which are consistent with
previous reports (Minami et al., 1992, 1994a; Tsukamoto et al., 2010). A
time course (5, 10, 15, and 30min) and i.t. dose for each prostaglandin
(PGE2, 10 ng/animal and PGF2α, 300 ng/animal) that produced a
submaximal allodynic response were selected for subsequent assess-
ment of the effects of AS1069562, duloxetine, and amitriptyline.
Fig. 2. Analgesic effects of RTX on PGE2- (A) and PGF2α- (B) induced allodynia in mice. Subcutaneous injection of RTX (0.001 mg/kg) 24 h before i.t. injection of PGE2 (10 ng/
animal) (A) or PGF2α (300 ng/animal) (B). Desensitization of C-ﬁbers with RTX did not suppress PGE2-induced allodynia, but completely suppressed PGF2α-induced allodynia.
Data (the mean7S.E.M. for 8 mice) are presented as percentage of the maximum cumulative score. Normal (white column) represents i.t. injection of saline and s.c.
administration of solution of 10% EtOH, 10% Tween 80, and 80% saline, while control (black column) represents i.t. injection of prostaglandin and s.c. administration of
solution of 10% EtOH, 10% Tween 80, and 80% saline. ###Po0.001 by Student's t test compared with normal group. nnnPo0.001 by Student’s t test compared with
control group.
Fig. 3. Analgesic effects of AS1069562 (A), duloxetine (B), and amitriptyline (C) on PGE2-induced allodynia in mice. Oral administration of AS1069562 (3, 10, and 30 mg/kg)
30 min prior (A), duloxetine (3, 10, and 30 mg/kg) 240 min prior (B), and amitriptyline (10, 30, and 100 mg/kg) 60 min prior (C) to i.t. injection of PGE2 (10 ng/animal).
AS1069562 (30 mg/kg) and duloxetine (10 and 30 mg/kg) signiﬁcantly ameliorated PGE2-induced allodynia, while amitriptyline at doses up to 100 mg/kg did not. Data (the
mean7S.E.M. for 8 mice) are presented as percentage of the maximum cumulative score. Normal (white column) represents i.t. injection of saline and p.o. administration of
distilled water, while control (black column) represents i.t. injection of prostaglandin and p.o. administration of distilled water. ###Po0.001 by Student's t test compared
with normal group. nnPo0.01, nnnPo0.001 by Dunnett's test compared with control group.
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3.3. Analgesic effects of RTX on prostaglandin-induced allodynia in
mice
To investigate the involvement of C-ﬁbers in prostaglandin-
induced spinal hypersensitivity, we determined the effects of
RTX on PGE2- and PGF2α-induced allodynia. Desensitization of
C-ﬁbers with systemic RTX (0.001 mg/kg s.c.) completely sup-
pressed allodynia induced by PGF2α (Fig. 2B) but not PGE2
Fig. 4. Analgesic effects of AS1069562 (A), duloxetine (B), and amitriptyline (C) on PGF2α-induced allodynia in mice. Oral administration of AS1069562 (3, 10, and 30 mg/kg)
30 min prior (A), duloxetine (3, 10, and 30 mg/kg) 240 min prior (B), and amitriptyline (10, 30, and 100 mg/kg) 60 min prior (C) to i.t. injection of PGF2α (300 ng/animal).
AS1069562 (30 mg/kg) and amitriptyline (30 and 100 mg/kg) signiﬁcantly ameliorated PGF2α-induced allodynia, while duloxetine at doses up to 30 mg/kg did not. Data (the
mean7S.E.M. for 8 mice) are presented as percentage of the maximum cumulative score. Normal (white column) represents i.t. injection of saline and p.o. administration of
distilled water, while control (black column) represents i.t. injection of prostaglandin and p.o. administration of distilled water. ###Po0.001 by Student's t test compared
with normal group. nPo0.05, nnPo0.01, nnnPo0.001 by Dunnett’s test compared with control group.
Fig. 5. Effects of (S)–WAY100135 (A) and SR57227 (B) on antinociceptive effect of AS1069562 in PGF2α-induced allodynia in mice. Oral administration of AS1069562 (30 mg/
kg) 30 min prior to i.t. injection of PGF2α (300 ng/animal). Intrathecal injection of (S)–WAY100135 (5-HT1A receptor antagonist) (2 nmol/animal) (A) and SR57227 (5-HT3
receptor agonist) (2 nmol/animal) (B) 30 min prior to that of PGF2α. The analgesic effect of AS1069562 in PGF2α-induced allodynia was signiﬁcantly blocked by (S)–
WAY100135 and by SR57227. Data (the mean7S.E.M. for 8 mice) are presented as percentage of the maximum cumulative score. Normal (white column) represents i.t.
injection of saline and p.o. administration of distilled water, while control (black column) represents i.t. injection of prostaglandin and p.o. administration of distilled water.
###Po0.001 by Student’s t test compared with normal group. nnPo0.01, nnnPo0.001 by Student's t test compared with control group. †Po0.05 by Student's t test compared
with AS1069562-treated group.
Table 1
Ki value of AS1069562 and duloxetine for 5-HT receptor subtypes.
5-HT receptor subtype 5-HT1A (μM) 5-HT1B (μM) 5-HT2B (μM) 5-HT3 (μM)
AS1069562 1.4 2.5 1.5 2.6
Duloxetine 4.4 3.4 0.40 15
Values are expressed as the mean.
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(Fig. 2A). These results demonstrate that the hyperexcitability of C-
ﬁbers plays a major role in triggering allodynia induced by PGF2α
but not PGE2.
3.4. Analgesic effects of AS1069562, duloxetine, and amitriptyline on
prostaglandin-induced allodynia in mice
To investigate the spinal antinociceptive mechanism of AS10
69562 compared with duloxetine and amitriptyline, we assessed
the effects of AS1069562, duloxetine, and amitriptyline on tactile
allodynia in PGE2- and PGF2α-induced allodynia models. Analgesic
effects on PGE2-induced allodynia are shown in Fig. 3, and those
on PGF2α-induced allodynia in Fig. 4. AS1069562 signiﬁcantly
ameliorated PGE2-induced allodynia at a p.o. dose of 30 mg/kg
(Fig. 3A), and duloxetine also signiﬁcantly improved PGE2-induced
allodynia at p.o. doses of 10 and 30 mg/kg (Fig. 3B). However,
amitriptyline did not signiﬁcantly improve PGE2-induced allodynia
even at p.o. doses up to 100 mg/kg (Fig. 3C). AS1069562 signiﬁ-
cantly ameliorated PGF2α-induced allodynia at a p.o. dose of
30 mg/kg (Fig. 4A), and amitriptyline also signiﬁcantly ameliorated
PGF2α-induced allodynia at p.o. doses of 30 and 100 mg/kg
(Fig. 4C). However, duloxetine did not signiﬁcantly ameliorated
PGF2α-induced allodynia even at p.o. doses up to 30 mg/kg
(Fig. 4B). These results demonstrate that AS1069562 inhibits both
PGE2 and PGF2α-induced allodynia, while duloxetine only inhibits
non-C-ﬁber-triggered allodynia and amitriptyline only inhibits
C-ﬁber-triggered allodynia.
To elucidate the mechanism by which AS1069562 induces
broader effects on prostaglandin-induced allodynia than dulox-
etine, we co-administered the 5-HT1A receptor antagonist (S)–
WAY100135 and 5-HT3 receptor agonist SR57227 with AS1069562
in the PGF2α-induced allodynia model. Saline was used as a vehicle
control for (S)–WAY100135 and SR57227. The analgesic effect of
AS1069562 at 30 mg/kg on PGF2α-induced allodynia was signiﬁ-
cantly blocked by 75% following i.t. co-injection of (S)–WAY100135
at 2 nmol (Fig. 5A) and by 66% following i.t. co-injection of
SR57227 at 2 nmol (Fig. 5B). These results demonstrate that
agonism of the 5-HT1A receptor and antagonism of the 5-HT3
receptor are involved in the analgesic effects of AS1069562 in a
mouse model of PGF2α-induced allodynia.
4. Discussion
Prostaglandins are generated by cyclooxygenase (COX)-2 in the
spinal cord and play an important role in the development and
maintenance of hypersensitivity following nerve injury (Ma et al.,
2002; Seybold et al., 2003). Expressions of COX-2 and EP1 receptor
have been reported to increase in injured human nerves
(Durrenberger et al., 2006). COX-2 levels were also found to be
elevated in nerve ﬁbers of patients with chronic pain (Durrenberger
et al., 2006). In addition, in rat models of CCI and spinal nerve
ligation-induced neuropathic pain, COX-2 expressionwas found to be
increased in both injured nerves and ipsilateral dorsal spinal cord
(Durrenberger et al., 2004; Zhao et al., 2000), and prostaglandins
were produced and released in the spinal cord following peripheral
nerve injury (Dirig and Yaksh, 1999). Further, PGE2 signaling via the
EP1 receptor has been reported to contribute to human pain
hypersensitivity (Sarkar et al., 2003). Taken together, these ﬁndings
suggest that prostaglandins may be involved in the development and
maintenance of neuropathic pain in humans and rodents. We there-
fore consider the prostaglandin-induced allodynia model to be
predictive of clinical efﬁcacy, particularly for prostaglandin-involved
pain. Intrathecal administration of PGE2 and PGF2α induces tactile
allodynia by facilitating glutamate release from presynaptic terminals
at the spinal cord dorsal horn via different mechanisms between the
two (Minami et al., 1992, 1994a, 1994b; Muratani et al., 2003;
Tsukamoto et al., 2010). In addition, descending 5-HT and norepi-
nephrine systems presynaptically inhibit the glutamate release
from the non-C- and C-afferent ﬁbers at the spinal cord dorsal
horn (Yoshimura and Furue, 2006). We recently conﬁrmed through
microdialysis assay that AS1069562 and duloxetine elevated extra-
cellular 5-HT and norepinephrine levels in rat spinal dorsal horn
(Murai et al., 2014). We therefore speculate that AS1069562 and
duloxetine may exert analgesic effects primarily mediated at the
spinal level. To clarify the spinal antinociceptive mechanisms of
AS1069562, duloxetine, and amitriptyline, which facilitate descend-
ing 5-HT and norepinephrine systems, we evaluated their effects in
i.t. PGE2- and PGF2α-induced allodynia models.
We investigated the effects of RTX on PGE2- and PGF2α-induced
allodynia to clarify the involvement of C-ﬁbers. Desensitization of
C-ﬁbers with systemic RTX signiﬁcantly suppressed hypersensi-
tivity induced by PGF2α but not PGE2, suggesting that hyperexcit-
ability of C-ﬁbers plays a major role in triggering PGF2α- but not
PGE2-induced allodynia. PGE2- and PGF2α-induced allodynia
models are therefore useful when investigating which type of
ﬁber is involved in the analgesic effect of a drug. Findings from a
study of capsaicin-treated neonatal mice suggested that capsaicin-
insensitive Aβ-ﬁbers are involved in PGF2α-induced mechanical
allodynia, while capsaicin-sensitive C-ﬁbers are involved in
PGE2-induced allodynia (Minami et al., 1999). Whether or not
the capsaicin-sensitive ﬁbers of neonatal mice destroyed by
capsaicin treatment are restored at a later age remains
unclear. However, streptozotocin-induced diabetes in neonatal
capsaicin-treated mice reportedly caused the reappearance of
intraplantar capsaicin-induced biting-licking behavior and
increased capsaicin receptor-immunoreactive neurons in the dor-
sal root ganglia (Rashid et al., 2003). In addition, RTX treatment
was reported to cause a depolarization block in the short term and
ablation of transient receptor potential vanilloid 1 expressing
nerve terminals in the long term (Jeffry et al., 2009). We therefore
administered RTX 24 h prior to prostaglandin injection to desen-
sitize C-ﬁbers.
AS1069562 signiﬁcantly alleviated both PGE2- and PGF2α-induced
allodynia, while duloxetine signiﬁcantly alleviated only PGE2-induced
allodynia and amitriptyline signiﬁcantly ameliorated only PGF2α-
induced allodynia. Taken together with ﬁndings for RTX efﬁcacy
against PGE2- and PGF2α-induced allodynia, these results indicate that
AS1069562 inhibits both C-ﬁber- and non-C-ﬁber-triggered allodynia,
while duloxetine inhibits only non-C-ﬁber-triggered allodynia and
amitriptyline inhibits only C-ﬁber-triggered allodynia. AS1069562 is
therefore suggested to have broader analgesic effects than duloxetine
and amitriptyline due to amelioration of both C-ﬁber- and non-
C-ﬁber-triggered allodynia.
We recently found that AS1069562 signiﬁcantly improved both
mechanical allodynia and thermal hyperalgesia in a rat model of
CCI-induced neuropathic pain (Murai et al., 2014). In that study,
duloxetine only signiﬁcantly ameliorated mechanical allodynia
and amitriptyline only thermal hyperalgesia. In addition, desensi-
tization of C-ﬁbers with systemic RTX completely suppressed CCI-
induced thermal hyperalgesia but only partially suppressed CCI-
induced mechanical allodynia (Murai et al., 2014). These previous
ﬁndings suggest that the hyperexcitability of C-ﬁbers plays a major
role in thermal hyperalgesia and is partially responsible for
mechanical allodynia in CCI rats, and that AS1069562 inhibits
hypersensitivity triggered by both C-ﬁbers and non-C-ﬁbers.
In contrast, duloxetine only inhibits non-C-ﬁber-triggered hyper-
sensitivity and amitriptyline only inhibits C-ﬁber triggered hyper-
sensitivity, ﬁndings are consistent with those of the present
study. These ﬁndings suggest that AS1069562 may have an
antinociceptive mechanism distinct from that of duloxetine and
amitriptyline.
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The mechanism by which AS1069562, unlike duloxetine, inhi-
bits C-ﬁber-triggered hypersensitivity has not yet been elucidated.
To determine whether or not other mechanisms contribute to the
relatively broad range of analgesic effects AS1069562 compared to
duloxetine, we investigated the afﬁnity of AS1069562 and dulox-
etine for 5-HT receptors. AS1069562 exhibited afﬁnity for the
5-HT1A, 5-HT1B, 5-HT2B, and 5-HT3 receptors with similar poten-
cies regarding the binding of 5-HT receptors and inhibition of 5-HT
and norepinephrine uptake (0.21- to 3.1-fold difference) (Shimizu-
Sasamata et al., 1993). In contrast, AS1069562 exhibited no
appreciable afﬁnity for the 5-HT2A, 5-HT2C, 5-HT4, 5-HT5A, 5-HT6,
or 5-HT7 receptors (data not shown). Further, the potencies of
duloxetine for binding 5-HT receptors and inhibiting 5-HT and
norepinephrine uptake differed substantially (57- to 5769-fold
difference) (Wong et al., 1993). The activation of the spinal
5-HT1A receptor and inhibition of the spinal 5-HT3 receptor are
considered to produce analgesic effects. For example, the 5-HT1A
receptor agonist F13640 decreased allodynic responses to tactile
and thermal stimulation in rats with spinal cord or sciatic nerve
injury (Colpaert et al., 2002). Further, 5-HT3 receptor antagonist
reduced the second phase of formalin-induced nociceptive beha-
vior and inhibited thermal and mechanical evoked neuronal
responses of wide dynamic range neurons in rats 14 days after
spinal nerve ligation (Okamoto et al., 2004; Suzuki et al., 2004).
AS1069562 exhibits afﬁnity for 5-HT1A and 5-HT3 receptors and
near equal potency for 5-HT reuptake inhibition; and activation of
the spinal 5-HT1A receptor and inhibition of the spinal 5-HT3
receptor have been reported to produce analgesic effects. We
therefore investigated the effects of AS1069562 on 5-HT1A and
5-HT3 receptors to determine whether or not activation of the
spinal 5-HT1A receptor and inhibition of the spinal 5-HT3 receptor
contribute to the analgesic mechanisms of AS1069562 differing
from those of duloxetine. The analgesic effect of AS1069562 on
PGF2α-induced allodynia was signiﬁcantly blocked by i.t. injection
of 5-HT1A receptor antagonist (S)–WAY100135 and 5-HT3 receptor
agonist SR57227, suggesting involvement of agonistic action of the
spinal 5-HT1A receptor and antagonistic action of the spinal 5-HT3
receptor in the antinociceptive effects of AS1069562 in C-ﬁber-
triggered allodynia. The 5-HT1A and 5-HT3 receptors have been
reported to be involved in C-ﬁber hypersensitivity; for example,
5-HT1A receptor knock-out mice and 5-HT1A receptor antagonist-
treated wild-type mice exhibited increased sensitivity in a hot-
plate test (Kayser et al., 2007), 5-HT3 receptor agonist-treated rats
exhibited increased excitability of C-ﬁber axons in their sural
nerve (Lang, et al., 2006), and 5-HT3 receptor antagonist-treated
rats showed reduced neuronal nociceptive reactions to thermal
stimuli (Ali et al., 1996), all of which are consistent with our
present results. An agonistic action of 5-HT1A receptor and an
antagonistic action of 5-HT3 receptor might contribute to the
different analgesic effects of AS1069562 and duloxetine, although
further investigation is required.
The mechanism by which AS1069562, unlike amitriptyline,
inhibits non-C-ﬁber-triggered hypersensitivity has not yet been
elucidated. While amitriptyline at a concentration of 1 mM has
been reported to have signiﬁcant afﬁnity for the α2-adrenergic
receptor (98% inhibition) (Werling et al., 2007), AS1069562 at
10 mM had no appreciable afﬁnity for α2-adrenergic receptors
(o50% inhibition) (data not shown). Given that the α2-adrenergic
receptors are coupled to the Gi/o subunit and are expressed in the
spinal cord dorsal horn (Olave and Maxwell, 2004), their activation
decreases transmitter release and exerts an inhibitory effect on the
sensory transmission in the spinal cord. Further, i.t. activation of
α2-adrenergic receptors produces an analgesic action in animal
models of chronic pain (Asano et al., 2000; Fairbanks et al., 2002).
In an electrophysiological study, norepinephrine inhibited C-ﬁber-
and non-C-ﬁber-mediated sensory transmission to substantia
gelatinosa neurons via activation of the α2-adrenergic receptor
found in primary afferent terminals, with inhibition being more
effective in non-C-ﬁber- than C-ﬁber-mediated transmission
(Kawasaki et al., 2003). These reports suggest that inhibition of
α2-adrenergic receptors might contribute to the distinct analgesic
mechanisms of AS1069562 compared to amitriptyline, as only the
latter has the potential to inhibit α2-adrenergic receptors, which
contribute to analgesic effects by primarily inhibiting non-C-ﬁber-
triggered hypersensitivity. However, further investigation is
needed prior to the adoption of this hypothesis.
In conclusion, the primary outcome of this study is that
AS1069562 inhibits both C-ﬁber- and non-C-ﬁber-triggered allo-
dynia, while duloxetine inhibits only non-C-ﬁber-triggered allo-
dynia and amitriptyline only C-ﬁber-triggered allodynia. The
secondary outcome of this study is the suggestion that the
antinociceptive effects of AS1069562 may be attributable to not
only 5-HT and norepinephrine reuptake inhibition but also its
effects on spinal 5-HT1A and 5-HT3 receptors. Taken together, these
ﬁndings suggest that AS1069562 may have a broader spinal
analgesic mechanism than that of duloxetine or amitriptyline.
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